Ongoing clinical trials in molecular imaging and radiotheranostics. Sorted by date of last update.
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Phase 1
Last update: September 23
Comparing Retreatment of Lu-177-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Phase 2
A Dose Finding Study of [Lu-177]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Last update: September 22
An Open-label Study of Lutetium (Lu-177) Vipivotide Tetraxetan (AAA617) in Combination with ARPI versus AAA617 in PSMA Positive First-line mCRPC (PSMAndARPI)
An Open-label Study Comparing Lutetium (Lu-177) Vipivotide Tetraxetan versus Observation in PSMA Positive OMPC. (PSMA-DC)
Phase 3
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
Open-label Study Comparing AAA817 versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [Lu-177]Lu-PSMA Targeted Therapy (PSMAcTION)
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination with Durvalumab and Bevacizumab Therapy in People with Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)
Last update: September 21
Radioimmunotherapy with Lu-177 Labeled 6A10 Fab-fragments in Patients with Glioblastoma After Standard Treatment (RIT in GBM)
A Phase Ib/II Open-label Study of AMO959 with Lutetium (Lu-177) Vipivotide Tetraxetan (AAA617) in Combination with ARPI in Adult Participants with PSMA-positive mCRPC
Last update: September 18